IL2 and neoplasm: Clinical trials based on vaccination with 210 M antigen, alone or in combination with interleukin-2 (IL-2), have demonstrated the induction of peptide- and tumor-specific cytotoxic T-lymphocyte responses in peripheral blood [106,107].